2480-93-5

Basic information

• Product Name: N-tert-Butoxycarbonyl-N'-benzyloxycarbonyl-L-ornithine
• Synonyms: (S)-5-(((Benzyloxy)carbonyl)aMino)-2-((tert-butoxycarbonyl)aMino)pentanoic acid;N^d-Benzyloxycarbonyl-N^a-Boc-L-ornithine, 98%;Z-Orn(Boc);(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-(phenylmethoxycarbonylamino)pentanoic acid;Boc-Orn(Z)-OH >=98.0% (TLC);Nα-Boc-N?-Z-L-ornithine99%;Ndelta-Benzyloxycarbonyl-Nalpha-Boc-L-ornithine;N-DELTA-Z-N-ALPHA-BOC-L-ORNITHINE
• CAS NO: 2480-93-5
• Molecular Formula: C₁₈H₂₆N₂O₆
• Molecular Weight: 366.41
• Product Categories: Amino Acid Derivatives;Amino Acids;Ornithine [Org];Unusual Amino Acids;Amino Acids (N-Protected);Biochemistry;Boc-Amino Acids;Cbz-Amino Acids;Boc-Amino acid series
• Mol File: 2480-93-5.mol

Chemical Properties

• Melting Point: 92.0 to 95.0 °C
• Boiling Point: 579.1 °C at 760 mmHg
• Flash Point: 304 °C
• Appearance: /
• Density: 1.193 g/cm³
• Vapor Pressure: 2.99E-14mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: −20°C
• Solubility: almost transparency in Methanol
• PKA: 3.96±0.21(Predicted)
• BRN: 2783761
• CAS DataBase Reference: N-tert-Butoxycarbonyl-N'-benzyloxycarbonyl-L-ornithine(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-Butoxycarbonyl-N'-benzyloxycarbonyl-L-ornithine(2480-93-5)
• EPA Substance Registry System: N-tert-Butoxycarbonyl-N'-benzyloxycarbonyl-L-ornithine(2480-93-5)

Safety Data

• Safety Statements: 24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 2480-93-5(Hazardous Substances Data)

Usage

Chemical Properties

White powder

InChI:InChI=1/C18H26N2O6/c1-18(2,3)26-17(24)20-14(15(21)22)10-7-11-19-16(23)25-12-13-8-5-4-6-9-13/h4-6,8-9,14H,7,10-12H2,1-3H3,(H,19,23)(H,20,24)(H,21,22)/t14-/m0/s1

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 16937-91-0 N^ε-(benzyloxycarbonyl)ornithine 
• 16965-08-5 1,1-dimethylethyl 2,4,5-trichlorophenyl carbonate 
• 3304-51-6 N-carboxybenzyl-L-ornithine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 70-26-8 L-ornithine 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 159877-12-0 (R)-5-amino-2-((tert-butoxycarbonyl)amino)pentanoic acid 
• 352274-96-5 (R)-methyl 2-amino-5-(((benzyloxy)carbonyl)amino)pentanoate 
• 499775-38-1 (R)-2-((R)-5-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-pentanoylamino)-succinic acid dibenzyl ester 
• 499775-37-0 (S)-2-((R)-5-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-pentanoylamino)-succinic acid dibenzyl ester 
• 499775-34-7 (S)-2-((R)-5-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-pentanoylamino)-pentanedioic acid dibenzyl ester 
• 887476-53-1 Boc-(R)-Orn(Z)-OtBu 
• 499775-16-5 [(2S,5R)-5-(3-Benzyloxycarbonylamino-propyl)-3,6-dioxo-piperazin-2-yl]-acetic acid benzyl ester 
• 499775-15-4 [(2R,5S)-5-(3-Benzyloxycarbonylamino-propyl)-3,6-dioxo-piperazin-2-yl]-acetic acid benzyl ester 
• 499775-12-1 3-[(2S,5R)-5-(3-Benzyloxycarbonylamino-propyl)-3,6-dioxo-piperazin-2-yl]-propionic acid benzyl ester 
• 352274-97-6 Boc-L-Trp-D-Orn-OMe 
• 352274-82-9 ethyl (4RS)-7-benzyloxycarbonylamino-4-[N-(tert-butoxycarbonyl)-L-tryptophyl]amino-3-oxoheptanoate 
• 352274-84-1 3-({3-[2-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionylamino]-2-ethoxycarbonylmethyl-piperidine-1-carbonyl}-amino)-benzoic acid 
• 155919-76-9 Boc-Tyr(tBu)-D-Orn-2-Nal-D-Pro-OH 
• 155919-74-7 Boc-D-Orn(Z)-2-Nal-D-Pro-OBzl 

Relevant articles and documents

COMPOUND FOR IMPROVING L-ARGININE BIOAVAILABILITY

The present application relates to a compound which may be useful for mediating NO production and improving L-arginine bioavailability in a subject. Pharmaceutical compositions comprising the compound and methods of using the compound are also provided.

IMMUNOSTIMULATING AGENT

The present invention aims to provide an immunostimulating agent superior in an immunostimulatory effect, particularly a compound useful as a vaccine adjuvant, a pharmaceutical composition containing the compound, a vaccine containing the compound and an antigen. An immunostimulating agent containing at least one kind of a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS

The present invention provides organic compounds which are capable of releasing carbon monoxide under physiological conditions or pH trigger, and to the use of such compounds for conditioning a cell, tissue or organ, for example, to protect against ischaemic injury during a transplant event.

Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools

Fluorescently labelled NPY Y1 receptor (Y1R) ligands were synthesized by connecting pyrylium and cyanine dyes with the argininamide-type Y1R antagonist core structure by linkers, covering a wide variety in length and chemical nature, attached to the guanidine group. The most promising fluorescent probes had Y1R affinities (radioligand binding) and antagonistic activities (calcium assay) in the one- to two-digit nanomolar range. These compounds turned out to be stable under assay conditions and to be appropriate for the detection of Y1Rs by confocal microscopy in live cells. To improve the signal-to-noise ratio by shifting the emission into the near infrared, a new benzothiazolium-type fluorescent cyanine dye (UR-DE99) was synthesized and attached to the parent antagonist via a carbamoyl linker yielding UR-MK131, a highly potent fluorescent Y1R probe, which was also successfully applied in flow cytometry.

Synthetic studies on chlorofusin: Synthesis of the cyclic peptide portion

The cyclic peptide portion of chlorofusin was synthesized by condensation of the five segments, d-Ada-OTMSE, Boc-l.-Orn(Cbz), Boc-l-Thr-l-Ala, l-Asn(Tr)-d-Asn(Tr)-d-Leu-OTMSE, and Boc-l-Thr-d-Leu, followed by cyclization at the amide bond between d-Ada an

Novel acyl-dipeptide-like compounds, a method for preparing the same and pharmaceutical compositions containing such products

The invention relates to the field of chemistry and more specifically to the field of medicinal chemistry. The invention is directed to N-acyl-dipeptide-like compounds having the general formula I wherein substituents A, B, X, Y, R1, R2, and subscripts n, m, p and q have the same meanings as those given in the claims. The invention is equally directed to pharmaceutical compositions containing as an active ingredient at least one compound of general formula I either in acid or salt form with an organic or mineral base. The compounds persuant to the invention display interesting pharmacological properties which make them useful as drugs.

Design and synthesis of novel tubular and cage structures based on thiazole-containing macrolactams related to marine cyclopeptides

Tubular and cage structures, i.e. 16 and 18, have been synthesised from modified cyclic peptides following selective cyclotrimerisations of L-ornithine and L-glutamic acid thiazole amino acids under high dilution conditions.

Synthesis of RGD peptidomimetic analogues of 2,5-diketopiperazine

Synthesis of 3-(methylacetate)-6-(N-benzyloxypropylamino)-2,5- diketopiperazine 5 and its corresponding RGD analogues 9,11,15 and 16 has been achieved and their platelet aggregation inhibitory activity evaluated.

Synthesis and Biological Activity of the Novel Nitric Oxide Synthase Inhibitor Nω'-Hydroxy-Nω-methyl-L-arginine

Nω'-Hydroxy-Nω-methyl-L-arginine has been sythesised in eight steps from N5-(benzyloxycarbonyl)-L-ornithine and has been found to inhibit the biosynthesis of nitric oxide.

Synthesis of the putative L-arginine metabolite L-N(G)-hydroxyarginine

Syntheses of L-N(G)-hydroxyarginine (1), the putative biosynthetic precursor of nitric oxide, and the 15N labelled analogs 9 and 10 using L-ornithine as the enantiopure starting material is reported.